TC-2216
TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and is being researched for the treatment of anxiety and depression.[1]
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H17N3 |
Molar mass | 203.283 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
References
- Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372.
5-HT1AR agonists | |
---|---|
GABAAR PAMs |
|
Gabapentinoids (α2δ VDCC blockers) | |
Antidepressants |
|
Sympatholytics (Antiadrenergics) |
|
Others | |
|
nAChRs |
| ||||
---|---|---|---|---|---|
Precursors (and prodrugs) | |||||
See also: Receptor/signaling modulators • Muscarinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.